All In Biotech

Investigational drug · Phase 3

Fluoropyrimidine

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colorectal Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma, Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

221

Any phase or sponsor naming "Fluoropyrimidine"

First trial start

2022

Feb 12, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Fluoropyrimidine", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Colorectal Neoplasms
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Approved drugs for the same conditions: Colorectal cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Fluoropyrimidine" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3,575 on PubMed

Also in development for Colorectal Neoplasms

  • OlomorasibLY3537982Phase 36 trials

    Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis

  • SGM-101Phase 31 trial

    Surgimab · Colorectal Neoplasms

  • BLU-924SAR449336Phase 21 trial

    Blueprint Medicines Corporation · Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms

  • DM002Phase 21 trial

    Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

  • E7386Phase 21 trial

    Eisai · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.